Navigation Links
Orphan Drugs in Oncology Drug Pipeline Update 2013
Date:11/19/2013

London (PRWEB) November 19, 2013

This is a worldwide report on cancer drugs which have now or in the past received orphan drug status. This product will give you unique access not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. This designation will in many countries provide several years of marketing exclusivity if the product candidate is approved for the designated orphan indication. It also provides special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of applying for marketing approval.

There are today 303 companies plus partners developing 400 orphan drugs in oncology drugs in 2245 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 119 drugs. Orphan Drugs In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 290 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 281 out of the 283 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 66 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. DIA-NORD Conference on Rare Diseases and Orphan Products to Feature Patients Discussing Challenges to Diagnosis and Treatment
2. Early Registration Deadline on Monday for U.S. Conference on Rare Diseases and Orphan Products
3. AED.com and Rescue Heart Foundation Donate AED to Haitian Orphanage
4. Orphan Drugs Market Partnering Deals and Agreements by Healthcare Companies Reviewed in New Research Report at RnRMarketResearch.com
5. Georgia Partnership for TeleHealth and LSU Partner to Bring Telemedicine to Orphanage in Guatemala
6. Orphan Drug Market to Reach $112 Billion in 2017: Bcc Research
7. Ground Broken For New Orphanage In Africa Thanks To Living Fuel And FreeRide836 Kiteboarders
8. Tellurex Sends tPOD1™ to Light Up Orphanage in Uganda
9. FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa
10. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
11. First Pathfinder Awards announced tackling rare and orphan diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , ... August 03, 2015 , ... ... will be attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) ... , “We are pleased for the opportunity the AHDI conference provides us to ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... 2015 , ... For many “would be” entrepreneurs, starting a new business can prove to ... to start a business.” Neither needs be a major obstacle. , The U.S. has ... a business and be successful. The risks of starting a business can be high but ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... muscles and connective tissues of a woman’s pelvic organs (uterus, bladder, and ... straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the ...
(Date:8/2/2015)... ... 02, 2015 , ... Molecular biologists in New South Wales say a protein ... has just posted an article on the new research. Click here to read ... Ki67 expression in tissue samples from 42 patients with peritoneal mesothelioma and found a ...
Breaking Medicine News(10 mins):Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... Pyratine-6(TM) and Pyratine XR(TM)NAPA, Calif., March 31 Senetek ... engaged in the development of technologies that target the ... quarter and year ended December 31, 2008. Revenue for ... with $26,471,000 reported in 2007. Revenues for the ...
... 31 The following is a statement by Lois ... Senate Majority Leader Smith and Assembly Speaker Silver for ... benefit under one of New York,s most beneficial programs ... program was in danger of losing more than $50 ...
... CITY, Mo., March 31 DST Systems, Inc. (NYSE: ... 50% of Argus Health Systems, Inc. ("Argus"). Argus is now ... in this press release may include forward-looking statements respecting DST ... DST,s views as of today, and actual actions or results ...
... DIEGO, March 31 - Orexigen(R) Therapeutics, Inc. (Nasdaq: ... on the treatment of obesity, today announced that ... as President and Chief Executive Officer of the ... M.D., Executive Chairman and Interim President and CEO. ...
... JACKSONVILLE, Fla., March 31 MSC ... products and services to post-discharge and post-injury workers, ... acquired Optimal Translation & Transportation, a national company ... acquisition further fortifies MSC,s position in the market, ...
... 31, 2009 -- Scientists who first established a link ... live in the intestine now are investigating whether the ... Researchers at Washington University School of Medicine in St. ... whether severely malnourished infants living in Malawi and Bangladesh ...
Cached Medicine News:Health News:Senetek PLC Reports 2008 Financial Results 2Health News:Senetek PLC Reports 2008 Financial Results 3Health News:State Budget Preserves State Pharmacy Program for Seniors (EPIC) 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:MSC Acquires Optimal Translation & Transportation 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 3Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 4
(Date:8/2/2015)... THE WOODLANDS, Texas , Aug. 3, 2015 ... today announced that the pivotal TELESTAR Phase 3 ... benefit of oral telotristat etiprate in treating cancer ... controlled by the current standard of care. Telotristat ... on Nobel Prize-winning technology, and is the company,s ...
(Date:7/31/2015)... 2015  Physicians and payers alone do not ... Patients are better informed and getting increasingly involved ... This shift in power is reshaping the healthcare ... marketing. As part of this evolving ... important to educate, communicate and engage patients throughout ...
(Date:7/31/2015)... July 31, 2015  In today,s ever-changing marketplace, call ... increasingly mobile, increasingly connected, and increasingly impatient with slow ... customer interaction channels and tools is driving call centers ... According to research by benchmarking firm, ... (OTC) segment in a call center study realize the ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: